Immune to Cancer: The CRI Blog

Let's spread the word about Immunotherapy! Click to share this page with your community.
Copy Link

Checkpoint Immunotherapy Approved for Patients with Stomach, Gastroesophageal, and Liver Cancer

September 25, 2017Arthur N. Brodsky, Ph.D.
Previously treated patients with these cancer types can now receive anti-PD-1 immunotherapy; nivolumab for HCC and pembrolizumab for advanced stomach or gastroesophageal cancer.

Read More

Filter by: